Elanco Animal Health Incorporated

Elanco Animal Health Incorporated

ELAN·NYSE

$24.58

+3.9%
HealthcareDrug Manufacturers - Specialty & Generic

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

At a Glance

Live Snapshot
Market Cap$12.28B
EPS-0.4700
P/E Ratio-52.30
Earnings Date08/06/2026
2.13%
Return on Invested Capital
39%
3Y-21.0%
5Y-638.0%
10Y-74.0%
-3.54%
Return on Equity
-164%
3Y+231.0%
5Y-46.0%
10Y+420.0%
-1.74%
Return on Assets
-165%
3Y+245.0%
5Y-45.0%
10Y+194.0%
Elanco Animal Health Incorporated

Elanco Animal Health Incorporated Management Team

ELAN · NYSE
MR

Mr. Robert M. VanHimbergen

Executive Vice President & Chief Financial Officer

Born 1976(Age 50)
male
MT

Mr. Todd S. Young J.D.

Executive Vice President & Chief Financial Officer

Compensation

$1,294,327

Born 1972(Age 54)
male
DR

Dr. Ramiro Martin Cabral

Executive Vice President & President of Elanco International

Compensation

$1,127,451

Born 1972(Age 54)
MT

Mr. Timothy J. Bettington

Executive Vice President of Corporate Strategy & Market Development

Compensation

$1,133,353

Born 1974(Age 52)
male
MD

Mr. David S. Kinard

Executive Vice President of Human Resources, Corporate Communications & Administration

Compensation

$722,576

Born 1967(Age 59)
male
DE

Dr. Ellen de Brabander Ph.D.

Executive Vice President of Research, Development & Regulatory Affairs

Compensation

$1,371,893

Born 1963(Age 63)
MS

Ms. Shiv O'Neill

Executive Vice President, General Counsel & Corporate Secretary

Born 1975(Age 51)
female
MJ

Mr. Jeffrey N. Simmons

President, Chief Executive Officer & Director

Compensation

$2,833,671

Born 1967(Age 59)
male
MJ

Mr. James M. Meer

Senior Vice President & Chief Accounting Officer

Born 1970(Age 56)
male
MC

Mr. Chris Keeley

Senior Vice President & Chief Information Officer

male
ML

Mr. Larbi Van Lier

Senior Vice President of Asia

male
MT

Ms. Tiffany Ann Kanaga

Vice President of Investor Relations & ESG

female
elan

Elanco Animal Health Incorporated Insider Positioning

ELAN · NYSE

During the last 12 months, insiders have purchased $1.14M worth of ELAN shares, with no selling activity reported.

3 Months

Bought

9.9K

199.78K

Sold

0

0.00

Net Activity

+200K

+$200K

3-6 Months

Bought

43.5K

937.90K

Sold

0

0.00

Net Activity

+938K

+$938K

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
SJN

Simmons Jeffrey N

Director, Officer: President, Ceo And Director

27.0K shares2 transactions

$578K

2
KLE

Kurzius Lawrence Erik

Director

10.0K shares1 transactions

$213K

3
MRA

Modi Rajeev A.

Officer: See Remarks

9.4K shares2 transactions

$196K

4
VRM

Vanhimbergen Robert M

Officer: Evp And Cfo

7.0K shares1 transactions

$150K

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $1.14M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

∞:1

Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.

Recent Trend (3 Months)

$200K

Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.

Insider Participation

High Buying

4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.

SEC Filings

ELAN - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
DEF 14A

DEF 14A 2025

N/A

March 27, 2025
May 16, 2025
2025
DEF 14A

DEF 14A 2024

N/A

April 19, 2024
May 30, 2024
2024
DEF 14A

DEF 14A

N/A

April 06, 2023
April 06, 2023
 
DEF 14A

DEF 14A 2022

N/A

April 06, 2022
May 18, 2022
2022
DEF 14A

DEF 14A 2021

N/A

March 25, 2021
May 19, 2021
2021
DEF 14A

DEF 14A 2020

N/A

April 08, 2020
May 21, 2020
2020
DEF 14A

DEF 14A 2019

N/A

April 03, 2019
May 08, 2019
2019
Showing 1 to 8 of 8 filings